Veru: Q2 Earnings Insights

 

Shares of Veru VERU remained unaffected after the company reported Q2 results.

Quarterly Results

Earnings per share fell 300.00% over the past year to ($0.04), which were in line with the estimate of ($0.04).

Revenue of $13,340,000 higher by 34.16% from the same period last year, which missed the estimate of $14,290,000.

Outlook

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

How To Listen To The Conference Call

Date: May 12, 2021

Time: 08:00 AM

ET Webcast URL: https://services.choruscall.com/mediaframe/webcast.html?webcastid=VV1xc3KL

Technicals

Company's 52-week high was at $24.57

52-week low: $2.30

Price action over last quarter: down 60.22%

Company Description

Veru Inc is a biopharmaceutical company focused on urology and oncology. It develops prescription products for benign prostatic hyperplasia hot flashes associated with cancer treatment, male infertility, and novel chemotherapies for a variety of cancers. The company currently operates in two reporting segments: Sexual health business and Research & development. Some of its products include Zuclomiphene, Veru-111, Veru-100, FC2, and Roman Swipes. The company generates the majority of its revenue from the United States.

Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...